An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

drug protocol number
CLEE011A2404
drug sponsor
Novartis
drug study
ribociclib / letrozole
drug trial site
NGHA-R , KFSH&RC-R , KFSH , KAMC , NGHA-J , KFMC
drug status
Completed
drug phase